Nucleosides have a wide range of physiological and pathophysiological roles in the human brain as modulators of a variety of neural functions. For example, adenosine, inosine, guanosine, and uridine participate in the mechanisms underlying memory, cognition, sleep, pain, depression, schizophrenia, epilepsy, Alzheimer's disease, Huntington's disease, and Parkinson's disease. Consequently, increasing attention is now being given to the speci fi c role of nucleosides in physiological and pathological processes in the human brain. Different elements of nucleoside system, including nucleoside concentrations, metabolic enzyme activity, and expression of nucleoside transporters and receptors, may be changed under normal and pathological conditions. The alterations suggest that interlinked elements of the nucleoside system are functioning in a tightly concerted manner.
Introduction
Nucleosides such as adenosine (Ado), guanosine (Guo), inosine (Ino), and uridine (Urd) have a role in the regulation of neuronal and glial functions in the brain (Burnstock et al. 2011 ; Dobolyi et al. 2011 ; Fields and Burnstock 2006 ; Haskó et al. 2004 ; Schmidt et al. 2007 ) . In addition, nucleosides participate in physiological and pathophysiological processes in the brain, such as the regulation of sleep and memory, epilepsy, Parkinson's disease, and Alzheimer's disease Huang et al. 2011 ; Lopes et al. 2011 ; Sperlágh and Vizi 2011 ) . Increasingly, nucleoside derivatives and uptake or metabolic inhibitors are being used in clinical or preclinical drug development for the treatment of different diseases, ranging from viral infections to neurodegenerative disorders (Boison 2011 ; Lopes et al. 2011 ; Parkinson et al. 2011 ) .
Regional differences occur in the nucleoside system of the human central nervous system (CNS). Nucleoside levels, metabolic enzymes, transporters, and receptors are unevenly distributed in the human brain ; Barnes et al. 2006 ; Dawson 1971 ; Fredholm et al. 2001 ; Jennings et al. 2001 ; Kovács et al. 1998 Kovács et al. , 2010a Nagata et al. 1984 ; Norstrand et al. 1984 ; Norstrand and Glantz 1980 ; Pennycooke et al. 2001 ; Phillips and Newsholme 1979 ; Ritzel et al. 2001 ) . In addition, nucleoside concentrations are dependent on age and gender (Kovács et al. 2010b ) . These results suggest region-, age-, and gender-dependent functions of nucleosides in the human brain. Correlations have been observed between the (1) S -(4-nitrobenzyl)-6-thioinosine (NBTI) binding site and the density of adenosine deaminase (ADA) immunoreactive neurons (Geiger and Nagy 1986 ) , (2) regional differences in nucleoside levels and the nucleoside metabolic enzyme activities and distribution of adenosine receptors (Kovács et al. 2010a ) , (3) ENT1 subtype of equilibrative nucleoside transporters (ENT1) and A 1 adenosine receptor subtype (A 1 R) density (Jennings et al. 2001 ) , and (4) A 1 R density and 5 ¢ -nucleotidase (5 ¢ NTs) levels (Fastbom et al. 1987 ) . Interactions have also been observed between ADA and A 1 Rs, resulting in the facilitation of agonist binding to A 1 Rs and the enhancement of receptor functionality in the human caudate nucleus (Gracia et al. 2008 ) . These results strengthen the hypothesis that the so-called "purinome" groups nucleoside and nucleotide receptors, transporters, metabolic enzymes and ligands together to organize purinergic signaling Volonté and D'Ambrosi 2009 ) . Complex anatomical, biochemical, and pharmacological analyses of the purinome are necessary to understand the functions of nucleoside system and to develop novel and safe drugs to treat various CNS diseases.
The aim of this chapter is to summarize the anatomical distribution of the nucleoside system in the human brain and to examine their potential for the development of pharmacological therapies. We focus on four nucleosides, Ado, Ino, Guo, and Urd. The available knowledge regarding the physiological and/or pathophysiological role of other nucleosides in the human brain is too limited for comprehensive evaluation. We brie fl y summarize some relevant features of the brain nucleoside system. Then we describe the anatomical distribution of nucleoside levels, metabolic enzymes, transporters, and receptors. Finally, we discuss their potential as targets of pharmacological therapeutics. .1 Nucleoside production, transport and receptor signaling. Abbreviations : 1: Nucleoside mono-and diphosphate kinases and nucleoside di-and triphosphate phosphatases; 2: GMPR GMP reductase; 3: GMPS GMP synthetase; 4: IMPDH IMP dehydrogenase; 5: AMPDA AMP deaminase; 6: ASL Adenylosuccinate lyase; 7: ASS Adenylosuccinate synthetase; 8: UCK Uridinecytidine kinase; 9: 5 ¢ NT 5 ¢ -Nucleotidase; 10: ADK Adenosine kinase; 11: UP Uridine phosphorylase; 12: PNP Purine nucleoside phosphorylase; 13: GDA Guanine deaminase; 14: XO Xanthine oxidase; 15: ADA Adenosine deaminase; 16: MTAP 5 ¢ -deoxy-5 ¢ -methylthioadenosine phosphorylase; 17: SAHH S-adenosylhomocysteine hydrolase; 18: APRT Adenine phosphoribosyltransferase; 19: HGPRT Hypoxanthine phosphoribosyltransferase (hypoxanthine-guanine phosphoribosyltransferase); 20: ecto-ATPase; 21: ecto-ADPase; 22: ecto-5 ¢ NT ecto-5 ¢ -nucleotidase (eN); 23: ecto-ADA ecto-adenosine (GDA; Fig. 29.1 ). In the fi nal step of purine catabolism in the human brain, Xn is converted to uric acid (UA) by xanthine oxidase (XO). The following enzymes regulate the extracellular (EC) Ado concentration: ecto-5 ¢ -nucleotidase (eN), ectoadenosine kinase (ecto-ADK), and ecto-adenosine deaminase (ecto-ADA) (Fernández et al. 2010 ; Firestein et al. 1999 ; Ipata et al. 2011 ; Yegutkin 2008 ; Zimmermann 1996 ) (Fig. 29.1 ).
Transporters
Nucleosides are transported into and released from brain cells via nucleoside transporters ( Fig. 29.1 ). Two types of nucleoside transporters are expressed in the human brain. The equilibrative nucleoside transporter family (ENT transporters; bidirectional facilitated diffusion) contains four ENT transporter types: ENT1-ENT4. NBTI partially inhibits ENTs at the nM concentration range ("es": equilibrative, NBTI sensitive type of ENTs, e.g., ENT1), whereas NBTI insensitive transporters are inhibited by NBTI only at the m M concentration range ("ei": equilibrative, NBTI insensitive type of ENTs, e.g., ENT2). The concentrative nucleoside transporter family (CNT transporters; unidirectional, sodium-dependent) includes six CNT transporter types (N1-N6) that are classi fi ed based on the types of nucleosides transported and sodium transport coupling Barnes et al. 2006 ; Jennings et al. 2001 ; Parkinson et al. 2011 ; Pennycooke et al. 2001 ; Ritzel et al. 2001 ) .
Receptors
All four known adenosine receptor subtypes (A 1 , A 2A , A 2B , and A 3 : also known as P1 receptors) have been identi fi ed in the human brain Jennings et al. 2001 ) . Adenosine receptors are G-protein-coupled receptors (GPCR; Fig. 29 .1 ). A 1 Rs couple to "inhibitory" G-proteins (G i and G 0 ) and inhibit adenylate cyclase (AC). A 2A Rs and A 2B Rs, however, stimulate AC using "stimulatory" G-proteins (G S ). A 2A Rs may also activate AC via G olf -proteins. Similar to A 1 Rs, A 3 Rs inhibit AC by coupling with G i -proteins. G q proteins can couple to A 2B and A 3 Rs and stimulate phospholipase C (PLC) activity. A 1 Rs can also stimulate PLC and modulate the activity of K + and Ca 2+ channels. In addition, the existence of yet unidenti fi ed nucleoside receptors cannot be excluded. For example, a novel subtype of adenosine receptors (A 4 ) has been proposed based on electrophysiological and pharmacological criteria in the brain (Corn fi eld et al. 1992 ; Luthin and Linden 1995 ; Tucker and Linden 1993 ) . It is also conceivable that Urd, Guo, and Ade have their own receptors (UrdR, GuoR, AdeR, respectively; Fig. 29 .1 ) that are used to execute certain functions in the nervous system (Bender et al. 2002 ; Borrmann et al. 2009 ; Kimura et al. 2001 ; Schulte and Fredholm 2003 ; Traversa et al. 2002 ) .
Anatomical Distribution of the Nucleoside System in the Human Brain

Distribution of Nucleoside Levels
The concentration of nucleotide triphosphates, such as adenosine triphosphate (ATP), guanosine triphosphate (GTP), uridine triphosphate (UTP), and cytidine triphosphate (CTP), are 2-3 orders of magnitude higher (0.2-5 mM) in the human brain than that of nucleosides are. Consequently, the degradation of nucleotide triphosphates ( Fig. 29.1 ) may increase the levels of corresponding nucleosides over baseline concentrations. For example, a 5-60 min period of ischemia was found to cause rapid degradation of nucleotide triphosphates and increase the concentrations of nucleosides and their metabolites (Ado, Guo, Ino, Hyp, and Xn) by 2-150 times that of baseline (Berne et al. 1974 ; Bjerring et al. 2010 ; Eells and Spector 1983 ; Hagberg et al. 1987 ; Kovács et al. 2010a ; Melani et al. 2003 ; Traut 1994 ) . Both animal and human experiments have determined that nucleoside concentrations are unevenly distributed in different brain areas (Kékesi et al. 2006 ; Kovács et al. 2010a . Kovács and colleagues (Kovács et al. 2005 ) developed an extrapolation method that allows realistic estimates of the in vivo nucleoside levels from postmortem frozen and microwave-treated brain bank samples. Using this method, a nucleoside map of the human brain, consisting of 61 brain and 4 spinal cord areas, was constructed. High Ado (15.9-23.9 pmol/mg), Urd (44.1-66.2 pmol/ mg), Ino (107.7-161.5 pmol/mg), and Guo (17.7-26.4 pmol/mg) concentrations were observed in several regions, including the cochlear nuclei, vestibular nuclei, cerebellar cortex, supraoptic nucleus, fl occulonodular lobe, spinal trigeminal nucleus, temporal and occipital cortices, caudate nucleus, nucleus basalis, medial geniculate body, amygdala, spinal central gray, and ventral horn of the spinal cord (Table 29 .1 ). The lowest concentrations of Ado (1.4-7.9 pmol/mg), Urd (15.7-22.0 pmol/mg), .8 pmol/mg), and Guo (4.1-8.8 pmol/mg) were measured in the entorhinal cortex, septum, habenula, zona incerta, substantia nigra, locus coeruleus, preoptic area, pulvinar, and inferior colliculus (Table 29 .1 ). Nucleoside metabolites such as Hyp, Xn, and uracil/Ura, (Fig. 29 .1 ) were also unevenly distributed in the human brain (Kovács et al. 2010a ) .
Age and gender may modulate nucleoside expression. For example, the levels of Ino and Ado in the frontal cortex increase with age. Urd, Ino, and Guo concentrations are higher in the frontal cortex and white matter of middle-aged women when compared to middle-aged men, whereas Ado levels are lower in the frontal cortex of both middle-aged and elderly women when compared to men (Kovács et al. 2010b ) . These results suggest that the nucleoside microenvironment in the human brain may be an important factor in the aging processes and nucleosides might play a part in the reduced vulnerability of female brains to excitotoxic insults (Kovács et al. 2010b ) . The levels of nucleosides in brain and spinal cord areas were compared to the grand average concentration values of the total brain and spinal cord areas (Kovács et al. 2010a ) . We also listed some brain and spinal cord areas, which are implicated in particular CNS diseases, even though their nucleoside levels did not differ from average values (these brain areas are labeled by "+" Svenningsson et al. 1997 ;  13 Fredholm et al. 2001 ; Abbreviations : Nucleosides-Ado Adenosine, Guo Guanosine, Ino Inosine, Urd Uridine; Nucleoside metabolizing enzymes-5 ¢ NT 5 ¢ -Nucleotidase, ADA Adenosine deaminase, ADK Adenosine kinase, GDA Guanine deaminase, PNP Purine nucleoside phosphorylase. For nucleoside transporter and nucleoside receptor abbreviations, see text 
Distribution of Nucleoside Metabolic Enzymes
Nucleoside metabolic enzymes form a complex network, including several alternative metabolic pathways (Ipata et al. 2011 ; (Fig. 29.1 ). The distribution and activity of nucleoside metabolic enzymes are uneven in the human brain, re fl ecting spatial differences in the nucleoside metabolic network. The distribution of 5 ¢ NTs, ADA, ADK, PNP, and GDA ( Fig. 29.1 ) activities in the human brain have been previously described (Dawson 1971 ; Nagata et al. 1984 ; Norstrand et al. 1984 ; Norstrand and Glantz 1980 ) (Table 29 .1 ).
The activities of 5 ¢ NT, PNP, and GDA are high in the thalamus (Table 29 .1 ). High to intermediate activity of 5 ¢ NT was found in several brain regions, including the temporal cortex, colliculus superior, basal ganglia, nucleus ruber, substantia nigra, amygdala, and hypothalamus. In contrast, the cerebellar cortex, lateral geniculate body, pallidum, corpus callosum, and mamillary body showed low activity levels of this enzyme.
Interestingly, the white matter of frontal, orbital, and temporal lobes contain the highest ADA activity, while only intermediate activity has been observed in the gray matter of these brain areas (Table 29.1 ). An intermediate ADA activity was also found, e.g., in the basal ganglia, pons, hippocampus, and thalamus. On the contrary, low ADA activity was measured in the cerebellum, hypothalamus, medulla oblongata, and spinal cord. Others have observed the highest level of ADA activity in the hypothalamus (Phillips and Newsholme 1979 ) .
High ADK activity has been found in the hypothalamus, pons, and hind brain. The temporal and occipital cortices and cerebellum show intermediate ADK activity, whereas the parietal lobe and frontal cortex contain low levels of this enzyme (Table 29 .1 ). GDA activity is also high in the mamillary body. Intermediate GDA activity was measured in the parietal cortex, basal ganglia, substantia nigra, and hippocampus, with the lowest activity in the cerebellum. High PNP activity was also revealed in the pons, midbrain and amygdala whereas low enzyme activity was demonstrated, e.g., in the putamen and spinal cord.
Spatial differences in the distribution of nucleosides are correlated with nucleoside metabolic enzyme activities and the neuron-glia ratio in the human brain (Kovács et al. 2010a ) . Nucleoside metabolism is different in neuronal and glial cells (Ceballos et al. 1994 ; Zoref-Shani et al. 1995 ) . Consequently, alterations in the glia/ neuron may cause regional differences in nucleoside levels. However, the correlation between the neuron-glia ratio and nucleoside levels in the human brain is weak (Kovács et al. 2010a ) . Importantly, the neuron-glia ratio is changed in some brain areas implicated in the development of major depressive and bipolar disorders, schizophrenia, Huntington's and Alzheimer's disease, and frontotemporal dementia (Bowley et al. 2002 ; Brauch et al. 2006 ; Harper et al. 2008 ; Öngür et al. 1998 ; Roos et al. 1985 ) . Table 29 .1 shows that altered nucleoside metabolic enzyme activity may result in an uneven distribution of nucleosides and their metabolites in the human brain (Kovács et al. 2010a (Table 29 .1 ). High 5 ¢ NT, PNP and GDA activities may result in low Guo levels in thalamic areas, such as the habenula, pulvinar, and zona incerta (Table 29.1 ) .
Altogether, these results suggest that the uneven distribution of nucleoside levels may be due to complex interactions between regionally different glia-neuron ratios and nucleoside metabolic enzyme activities.
Distribution of Nucleoside Transporters
The distribution of nucleoside transporters in the human brain is uneven, and the regionally different distribution of nucleoside transporters re fl ects the functional signi fi cance of nucleoside neuromodulation in different brain areas Barnes et al. 2006 ; Jennings et al. 2001 ; Pennycooke et al. 2001 ; Ritzel et al. 2001 ) .
ENT1 expression is high in the frontal and the parietal cortices, whereas the occipital and temporal lobe shows the highest ENT3 activity and high or intermediate ENT4 activity (Table 29 .1 ). Intermediate or low ENT3 and ENT4 density occurs in the frontal and parietal lobes. Low levels of ENT1 expression are found in the medulla oblongata and the pons, whereas these brain areas show high to intermediate ENT2 expression. ENT2 expression is low in cortical areas and the basal ganglia. All ENT transporters are expressed at intermediate levels in the thalamus. The hippocampus shows low or intermediate ENT levels with the exception of ENT4, which is expressed at high levels in this brain area.
CNT transporters are also widely distributed in the human brain. Relatively high expression of CNT subtypes (CNT1, CNT2, and CNT3) occurs in the cerebellum, putamen, hippocampus, and medulla oblongata (Table 29 .1 ).
Distribution of Nucleoside Receptors
The distribution of adenosine receptors in the brain re fl ects the physiological activity and effects of Ado in brain structures, whereas changes in the density of adenosine receptors may indicate functional and pathological changes (Boison 2005 ; Fastbom et al. 1986 Fastbom et al. , 1987 Jenner et al. 2009 ) .
Adenosine receptors are unevenly distributed in the human brain Jennings et al. 2001 ) (Table 29 .1 ). High expression of A 1 Rs has been measured in several cerebral cortical areas and the basal ganglia. The temporal cortex, thalamus, and hippocampus contain intermediate levels of A 1 Rs, whereas the cerebellum, midbrain, pons, and medulla oblongata show low density of this adenosine receptor type. A 2A Rs are expressed at high levels in the basal ganglia and high A 3 R density occurs in the cerebellum and hippocampus. In other brain areas, A 2A and A 3 Rs are expressed at lower levels. Uniform distribution of A 2B Rs, however, has been shown to occur.
Implications for Therapy
Drugs acting on the nucleoside system are widely used for therapeutic purposes (Table 29 .2 , Fig. 29.1 ). Nucleoside metabolic enzyme inhibitors are used in anticancer therapies and the treatment of gout. In addition, several different nucleoside transport inhibitors are used as coronary vasodilators. Drugs acting on adenosine receptors are also used as vasodilators and to treat cardiac arrhythmias, carcinomas, rheumatoid arthritis, acute renal failure, and asthma. In addition, some synthetic nucleosides (nucleoside drugs) are used in antiviral and anticancer therapies.
Some drugs acting on the adenosine system have already been tested for the potential to treat brain disorders (Table 29 .2 ). Based on its distribution and physiological roles in the CNS, the adenosine system has much wider potential for the treatment of pain, movement and mood disorders, schizophrenia, epilepsy, drug addiction, insomnia, multiple sclerosis, dementias, and stroke. Guanosine and Ino may also be neuroactive purines with therapeutic potential (Deutsch et al. 2005 ; Schmidt et al. 2007 ) . The recent discovery of pyrimidine nucleotide receptors and the emerging neural functions of Urd imply that this pyrimidine nucleoside could also have therapeutic applications in the future (Cansev 2006 ; Connolly and Duley 1999 ; Dobolyi et al. 2011 ) .
In the following sections, we discuss several neurological disorders where drugs acting on the nucleoside system may have therapeutic potential (Table 29. 2 ).
Movement Disorders
The initiation of movement is governed by the interaction of the motor cortex, the thalamus, and a circuit consisting of several members of the basal ganglia, including the striatum, globus pallidus, and substantia nigra. The underlying pathologies for Parkinson's and Huntington's diseases are loss of nigrostriatal dopaminergic cells and degeneration of GABA/enkephalin neurons projecting from the striatum to the external globus pallidus, respectively (Harris et al. 2009 ) .
Nucleosides and nucleoside metabolic enzymes are found in brain areas involved in movement disorders (Dawson 1971 ; Kovács et al. 2010a ; Nagata et al. 1984 ; Norstrand et al. 1984 ; Norstrand and Glantz 1980 ) (Table 29 .1 ). Nucleoside transporters are present in the caudate nucleus, putamen, globus pallidus, and substantia nigra (Barnes et al. 2006 ; Jennings et al. 2001 ; Ritzel et al. 2001 ) . Caudate nucleus, putamen, and globus pallidus contain high levels of A 1 and A 2A Rs (Jennings et al. 2001 ) . In particular, striatopallidal GABAergic enkephalin-containing neurons in the basal ganglia show the highest expression of A 2A Rs (Durieux et al. 2011 ; Popoli et al. 2007 ) . These A 2A Rs tightly interact structurally and functionally with the dopamine D2 receptor and have been suggested to drive striatopallidal output balance ) . In cases of dopaminergic hypofunction, A 2A R activation contributes to the overdrive of the indirect pathway (Schiffmann et al. 2007 ) . A 2A R antagonists (Table 29. 2 ), therefore, have the potential to restore this inhibitor imbalance. Consequently, these drugs have therapeutic potential in diseases of dopaminergic hypofunction such as Parkinson's disease. Indeed, A 2A R antagonists have been effective in a variety of animal models of Parkinson's disease Chen et al. 2001 ; Hodgson et al. 2010 ; Kanda et al. 1998 Kanda et al. , 2000 . Furthermore, caffeine ameliorates the freezing of gait that occurs in Parkinson's disease patients (Kitagawa et al. 2007 ) . A number of clinical trials are under way to evaluate the potential of A 2A R antagonists in the treatment of Parkinson's disease (Table 29. 2 ), and the modulation of A 1 and A 2A Rs may be effective in the treatment of Huntington's disease as well Chou et al. 2005 ; Popoli et al. 2007 ) .
Uridine might also be potentially effective in the treatment for Parkinson's disease. Coadministration of uridine monophosphate (UMP) and docosahexaenoic acid known to increase Urd levels and synapse formation in the brain increased striatal dopamine levels and alleviated the behavioral effects of 6-hydroxydopamine injections in a rat model of Parkinson's disease (Cansev et al. 2008 ) .
Addiction
Although the different classes of drugs of abuse in fl uence numerous neurotransmitter systems within the brain, all either directly or indirectly enhance the activity of the mesolimbic dopaminergic system. Within this system, ascending dopaminergic fi bers project from the ventral tegmental area to the prefrontal cortex and nucleus accumbens, areas that are involved in the rewarding effects of drugs of abuse (Lajtha and Sershen 2010 ; Willuhn et al. 2010 ) .
Similar to the striatum, the level of A 2A Rs is also particularly high in the nucleus accumbens Svenningsson et al. 1997 ) , an area that contains low to intermediate levels of nucleosides (Kovács et al. 2010a ) and ENT3, ENT4, and CNT3 transporters Barnes et al. 2006 ; Ritzel et al. 2001 ) (Table 29 .1 ). Based on the presence of nucleoside transporters in the nucleus accumbens, transport inhibitors might have therapeutic potential in the treatment of drug addiction and alcoholism (Table 29. 2 ). Indeed, adenosine transport in the nucleus accumbens decreases following chronic administration of morphine to rats (Brundege and Williams 2002 ) . Adenosine may inhibit the reward process via A 2A Rs (Baldo et al. 1999 ) . In animal models, A 2A R agonists inhibit cocaine selfadministration, while antagonists reinstate this behavior (Knapp et al. 2001 ; Weerts and Grif fi ths 2003 ) . Furthermore, mice lacking the A 2A R exhibit attenuated reward processes (Castane et al. 2006 ) . Some novel human data also supports the involvement of the adenosine system in addiction. An elevated A 2A R binding af fi nity was found in platelets of patients suffering from pathological gambling (Martini et al. 2011 ) . Clinical trials based on these data are expected in the near future .
Pain Management
Nociceptive impulses fi rst reach the posterior horn of the spinal cord. From here, information is transmitted to several brain regions involved in nociception. The reticular formation regulates arousal reactions and autonomic re fl exes to pain, and thalamic nuclei relay and differentiate the nociceptive stimuli. Speci fi c nuclei of the hypothalamus mediate autonomic and neuroendocrine responses. The limbic system mediates the emotional and motivation-related aspects of nociception, while the somatosensory cortex is mainly responsible for pain differentiation and localization (Apkarian et al. 2005 ) . Additional pathways descending from a handful of brain regions, including the periaqueductal gray, rostroventromedial medulla, lateral reticular nucleus, and some brainstem monoamine cell groups, modulate nociception (Heinricher et al. 2009 ) .
Nucleosides and their metabolic enzymes and transporters have been observed in different regions of large anatomical structures such as the spinal cord, medulla oblongata, midbrain, thalamus, hypothalamus, and diencephalon (Table 29 .1 ). However, there is little data on the presence of nucleoside system in the speci fi c areas of nociceptive circuitry in the brain, and further studies are needed. Nevertheless, a signi fi cant expression of A 1 Rs has been described in primary sensory neurons associated with nociceptive pathways (Lima et al. 2010 ) .
There is a great body of evidence indicating that the activation of A 1 Rs produces antinociception (Curros-Criado and Herrero 2005 ) . Mice lacking the A 1 R exhibit hyperalgesia (Johansson et al. 2001 ) . Consequently, drugs that target the nucleoside system have potential for the treatment of pain. GP-3269, an adenosine kinase inhibitor (Fig. 29.1 ) , and GW-493838, an A 1 R agonist, may be useful in the treatment of pain and migraines (Elzein and Zablocki 2008 ; Erion et al. 1997 ; Kowaluk and Jarvis 2000 ; McGaraughty et al. 2005 ; Wiesner et al. 1999 ) (Table 29 .2 ). Guanosine was also found to have an antinociceptive effect in mice (Schmidt et al. 2009 ) , suggesting that it may also be a potential target for the treatment of pain.
Mood Disorders
Anxiety, panic disorder, mania, and different forms of depression do not involve major neuronal degeneration in any brain regions. Nevertheless, animal studies and various imaging techniques have identi fi ed a number of limbic brain regions that play a role in the etiology of mood disorders. These regions include the prefrontal and cingulate cortices, septohippocampal circuits, amygdala, hypothalamus, and central gray matter of the midbrain (Garakani et al. 2006 ; Kalia 2005 ) . Neurons in the locus coeruleus and raphe nuclei are thought to modulate these systems, explaining the effects of noradrenergic and serotonergic drugs on mood disorders (Fava 2003 ) .
Only some of these structures have been studied for the presence of the elements of the nucleoside system (Table 29 .1 ). The amygdala is particularly rich in nucleosides (Kovács et al. 2010a ) . Intermediate or high activities of 5´NT and PNP occur in the amygdala and the frontal and cingulate cortices (Nagata et al. 1984 ; Norstrand and Glantz 1980 ) . Intermediate/low CNT2 and CNT3 levels are also observed in the amygdala and frontal cortex (Ritzel et al. 2001 ) . ENT4 is abundant only in the amygdala, while ENT1 is believed to be the major equilibrative nucleoside transporter subtype in the frontal cortex (Barnes et al. 2006 ; Jennings et al. 2001 ) . A high level of A 1 Rs is found in the frontal cortex. Similar to the stratium (Schiffmann et al. 2007 ) , the cortex also contains adenosine receptors both pre-and postsynaptically (Kirmse et al. 2008 ) . Some other important brain regions, including the periaqueductal gray and monoamine systems, however, have not been systematically investigated for the presence of nucleoside metabolic enzymes and transporters. Nevertheless, the nucleoside system is expected to be a target for new drugs to treat mood disorders ) . Caffeine, a competitive antagonist of the A 1 and A 2A Rs (Fredholm et al. 1999 ) , promotes anxious behavior both in animal models and humans (Klein et al. 1991 ) , and A 2A R polymorphisms are associated with increased incidence of panic disorder and depression (Hamilton et al. 2004 ; Lam et al. 2005 ; Tsai et al. 2006 ) . In addition, mice lacking A 1 or A 2A Rs demonstrate anxiogenic-like behaviors (Gimenez-Llort et al. 2002 ; Johansson et al. 2001 ; Ledent et al. 1997 ) . Indeed, the application of an A 1 R antagonist might be an effective treatment strategy for patients with anxiety disorders (Table 29. 2 ). Allopurinol has been found to elicit therapeutic effects in the treatment of mania (Akhondzadeh et al. 2006 ) (Table 29 .2 , Fig. 29.1 ). Chronically administrated Guo produced anxiolytic effects in mice (Vinadé et al. 2003 ) , suggesting a potential role of this purine nucleoside in the management of anxiety.
Schizophrenia
Pharmacological studies indicate the involvement of dopaminergic and glutamatergic neurons in the etiology of schizophrenia. A leading current hypothesis is that schizophrenia arises due to abnormalities in the dopamine-glutamate system of the corticostriatal pallidothalamic circuit, including the prefrontal cortex, nucleus accumbens, ventral tegmental area, mediodorsal thalamic nucleus, and ventral pallidum. Some drugs inducing drug dependence, probably by increasing the level of dopamine in the nucleus accumbens, also cause hallucinations suggesting that surplus dopamine may be a common ethiological factor. In addition to abnormalities in the corticostriatal system, alterations in the ventral limbic circuits of the dopamineglutamate system, including the hippocampus, enthorinal cortex, and basolateral amygdala, may also be involved (Ross et al. 2006 ) .
There is an intermediate to high level of nucleosides in most of the brain regions implicated in schizophrenia (Kovács et al. 2010a ) (Table 29 .1 ), and the evidence suggests that schizophrenia is associated with a hypofunctioning adenosine system . Adenosine levels can be increased by inhibiting adenosine transporters or xanthine oxidase with dypiridamole or allopurinol, respectively (Fig. 29.1 ). Both of these treatments had bene fi cial antipsychotic effects in clinical trials when administered in combination with haloperidol (Akhondzadeh et al. 2000 (Akhondzadeh et al. , 2005 (Table 29. 2 ). Furthermore, psychotic symptoms in schizophrenic patients are worsened by caffeine (Lucas et al. 1990 ) . An interaction between adenosine and the dopamine system (Ferré et al. 1997 ) or the glutamate system (De Mendonca et al. 1995 ; Gerevich et al. 2002 ) could be driving these effects. Indeed, A 2A R agonists and antagonists may have therapeutic potential for different types of psychosis (Table 29. 2 ).
In animal models, some of the effects of haloperidol were augmented by coadministration with Urd (Agnati et al. 1989 ; Myers et al. 1994 ) . Chronic Urd administration was also found to increase stereotypy scores and catalepsy induced by an acute haloperidol injection (Agnati et al. 1989 ) . Furthermore, chronic Urd treatment reduced expression of dopamine receptors and enhanced their turnover rate in the striatum (Farabegoli et al. 1988 ) . These data suggest that Urd coadministration might enhance the antipsychotic actions of traditional neuroleptics.
Moreover, the neuroprotective and neurotrophic effects of Guo may also be advantageous for the treatment of schizophrenia; Guo was found to attenuate hyperlocomotion induced by dizocilpine, a pharmacological model of schizophrenia, in mice (Tort et al. 2004 ) .
Epilepsy
Epilepsy is characterized by a variety of recurrent symptoms resulting from the synchronous or sustained discharge of a group of neurons. The pathophysiology of epilepsy is poorly understood, and so far, there is no clear association between the abnormal function of a speci fi c group of neurons and the genesis of seizures. There is some evidence, however, that the impairment of inhibitory signals, often occurring in the neocortex and hippocampus, may be primarily involved (Bertram 2009 ) .
In the human hippocampus, ADA and GDA have intermediate activity (Dawson 1971 ; Norstrand et al. 1984 ) (Table 29 .1 ). Adenosine and Ino levels are low, but intermediate concentrations of Guo and Urd are present (Kovács et al. 2010a ) . Based on their abundance, ENT4, CNT2, and CNT3 are believed to be the major nucleoside transporters in the hippocampus (Barnes et al. 2006 ; Ritzel et al. 2001 (Jennings et al. 2001 ) . Indeed, the interaction of Ado with the inhibitory A 1 R has been shown to have anticonvulsant effects in animal models (Barraco et al. 1984 ; Fedele et al. 2006 ) . As A 1 R agonists have peripheral cardiac and central sedative side-effects, adenosine kinase inhibitors (Fig. 29.1 ) have been used to indirectly increase Ado levels (Boison 2008 ) . These drugs were shown to have anticonvulsant properties . In particular, GP-3269, an adenosine kinase inhibitor, was found to be useful for the treatment of epilepsy Kowaluk and Jarvis 2000 ; McGaraughty et al. 2005 ; Wiesner et al. 1999 ) (Table 29. 2 ).
Recently, the distribution of A 2A Rs in the brain has been found to be altered in an animal model of human absence epilepsy (Wistar Albino Glaxo/Rijswijk rat: WAG/ Rij), both before and after appearance of absence seizures (D'Alimonte et al. 2009 ) . A low density of A 1 Rs was also found in the thalamic reticular nucleus in another animal model of human absence epilepsy (Genetic Absence Epilepsy Rat from Strasbourg: GAERS) when compared with control animals (Ekonomou et al. 1998 ) . These results suggest that adenosine receptors might represent a novel target for the treatment of absence epilepsy.
The anticonvulsant effects of Urd have also been hypothesized; Urd was found to reduce penicillin- (Roberts 1973 ; Roberts et al. 1974 ) , pentylenetetrazole- (Dwivedi and Harbison 1975 ) , and electroconvulsion-induced (Piccoli et al. 1971 ) seizures in experimental rodent models of epilepsy. Indeed, Urd is released following depolarization and inhibits unit activity (Dobolyi et al. 1999 (Dobolyi et al. , 2000 . Recently, Urd has been found to act as an antiepileptogen in hippocampal kindling models (Zhao et al. 2006 (Zhao et al. , 2008 . In addition, Guo prevented seizures induced by quinolinic acid and other glutamatergic agents (De Oliveira et al. 2004 ; Schmidt et al. 2000 ) . These data suggest that Urd and Guo also have antiepileptic potential.
Insomnia
EEG recordings and other evidence indicate that sleep affects most cortical areas. Sleep waves are generated by an interaction between cortical and thalamic circuits, including thalamic reticular and relay nuclei. Sleep states are regulated by speci fi c brain centers, and dysfunction of these regions leads to insomnia. Serotonergic and noradrenergic projections ascending from the brainstem and histaminergic cells in the tuberomamillary nucleus promote consciousness, while the preoptic area of the hypothalamus and cholinergic neurons in the basal forebrain and tegmental nuclei of the pons promote sleep. Orexinergic cells in the lateral hypothalamus may also have important on/off functions regarding sleep states (Datta and Maclean 2007 ; Saper 2006 ) . The involvement of Ado in regulating sleep has long been suspected due to the hypnotic effects of adenosine analogues (Radulovacki 1985 ) . The distribution of Ado and its inhibitory A 1 R and increases of Ado levels in metabolically challenged cells are relatively ubiquitous. Furthermore, caffeine and theophylline are widely used as stimulants of the CNS. Therefore, the hypothesis emerged that, during daytime activity, ATP is degraded to adenosine, which could induce sleep. Indeed, prolonged wakefulness is known to increase Ado levels in the basal forebrain that, in turn, may decrease the activity of cholinergic cells to promote sleep (Porkka-Heiskanen and Kalinchuk 2011 ) . A selective decrease in CNT2 mRNA levels was demonstrated in the cerebral cortex of sleep-deprived rats (Guillén-Gómez et al. 2004 ) . These data suggest that adenosine receptor agonists and nucleoside transport inhibitors might be effective in the treatment of sleep disorders (Table 29 .2 ).
Uridine was identi fi ed as an active component of a sleep-promoting substance puri fi ed from the brainstem of sleep-deprived rats (Borbely and Tobler 1989 ; Inoue 1986 ) . Infusion of Urd increased slow wave and paradoxical sleep (Honda et al. 1984 ) . Intraperitoneally injected Urd resulted in a dose-dependent appearance of slow-wave sleep when administered shortly before onset of the dark period (Honda et al. 1985 ) . Based on these data, drugs elevating Urd levels in the brain should be tested for the treatment of insomnia in future studies.
Dementia
Alzheimer's disease is a progressive, degenerative disease of the brain that is the most common cause of dementia in the elderly. Typical pathological features of Alzheimer's disease are neuritic plaques and neuro fi brillary tangles occurring primarily in the cholinergic basal forebrain and the hippocampus, frontal, parietal, and temporal lobes of the cerebral cortex (Peskind 1996 ) .
The cerebral cortex and the basal forebrain contain all elements of the nucleoside system (Table 29 .1 ). Neuroprotection achieved by manipulating the brain nucleoside system could be bene fi cial in the treatment of dementia. Animal models implicate the involvement of A 2A Rs in the development Alzheimer's disease. Caffeine and A 2A R antagonists prevent beta-amyloid (25-35)-induced cognitive de fi cits in mice ) . Additionally, caffeine elevates alertness and improves cognition in humans (Eskelinen et al. 2009 ; Ritchie et al. 2007 ) . These effects might be due to altered acetylcholine release by A 2A Rs (Cunha et al. 1995 ; Jin and Fredholm 1997 ) . In addition to receptor antagonists, propentofylline, an inhibitor of "es" nucleoside transporters, has established neuroprotective effects , and its administration to patients with Alzheimer disease and vascular dementia resulted in functional improvements in clinical trials (Mielke et al. 1998 ) .
Low to intermediate Ado levels but intermediate to high A 1 R density has been observed in brain areas implicated in Alzheimer disease (Table 29 .1 ), and loss of human hippocampal A 1 Rs has been shown in dementia patients (Deckert et al. 1998 ) . Therefore, A 1 receptor antagonists are potential targets for the treatment of dementia and cognitive disorders (Table 29. 2 ). Administration of a nucleosidenucleotide mixture reduced memory deterioration in elderly senescence-accelerated mice (Chen et al. 2000 ) . In addition, age-dependent alterations in the adenosine system have been found (Kovács et al. 2010b ; Meyer et al. 2007 ) . These fi ndings suggest that Ado might participate in the pathophysiology of learning and memory disorders, as well as the normal aging process.
In animal studies, Urd was found to improve certain types of memory function (Holguin et al. 2008 ; Teather and Wurtman 2003 . Therefore, increased Urd formation may mediate the positive effects of cytidine diphosphocholine (CDPcholine) on verbal memory in aging humans (Spiers et al. 1996 ) . Consequently, CDP-choline and other nutritional components that increase brain Urd levels (Wurtman et al. 2000 ) may be important, especially during the early phases of Alzheimer's disease ( Van der Beek and Kamphuis 2008 ; Wurtman et al. 2009 ) .
Recently, Guo has been found to protect against beta-amyloid-induced apoptosis (Pettifer et al. 2004 ) . This effect appeared to be mediated by the antiapoptotic properties of Guo (Di Iorio et al. 2004 ) . Guanosine was also found to modulate memory processes: its pretraining administration impaired retention of inhibitory avoidance responses in rats (Roesler et al. 2000 ) . Furthermore, the amnesic effects associated with GMP pretreatment are also dependent on its conversion to Guo (Saute et al. 2006 ) (Fig. 29.1 ). 
Stroke
In stroke, tissue damage is most often caused by ischemia resulting from an occluded blood vessel (Dietrich 1998 ) . Neuroprotection by manipulation of brain nucleoside system may be bene fi cial in stroke victims. Adenosine and other nucleosides are elevated during ischemia (Rudolphi et al. 1992 ) . While adenosine released from neurons or accumulated by the extracellular degradation of released ATP could reach a concentration ef fi cient for the activation of adenosine receptors, a pathophysiological release from neurons as well as glial cells occurs during an ischemic event (Latini and Pedata 2001 ) . Agonist stimulation of the A 1 R may inhibit excessive neuronal fi ring and may enhance local cerebral blood fl ow (O'Regan 2005 ) , reducing brain damage following experimentally induced ischemia in animals. Indeed, lacking the A 1 receptor exhibited decreased hypoxic neuroprotection in mice (Johansson et al. 2001 ) . Thus, Ado may be involved in ischemic preconditioning, an endogenous neuroprotective mechanism (Liu et al. 2009 ) . Consequently, drugs that act on adenosine receptors, adenosine metabolizing enzymes, and nucleoside transporters (Table 29 .2 , Fig. 29 .1 ) and increase EC Ado levels could be targets for the development of clinical therapeutics suitable for treatment of ischemic brain disorders (Stone 2002 ; Von Lubitz 2001 ) . Importantly, the effectiveness of all of these potential therapies may vary between patients due to differences in the spatial distribution of the nucleoside system (Table 29 .1 ). Indeed, the nucleoside system may be modulated differently in men and women (Kovács et al. 2010b ) . Changes in nucleoside levels in female brain cortical samples may serve as a protective mechanism against excitotoxic insults, suggesting that several normal and pathological brain functions are based on gender-dependent nucleoside microenvironments in humans.
Other nucleosides might also have neuroprotective functions in response to ischemic injury, and increasing their expression might be bene fi cial both during and after an ischemic attack. In animal models, Guo had neuroprotective effects in both in vitro and in vivo stroke models (Chang et al. 2008 ) . Inosine was also shown to reduce ischemic brain injury in rats (Shen et al. 2005 ) . Inosine and Guo preserved the viability of cultured astrocytes, neurons (Jurkowitz et al. 1998 ; Litsky et al. 1999 ) , and brain slices maintained under hypoxic or hypoglycemic conditions (Frizzo et al. 2002 ) . The potential neuroprotective effects of Guo are also supported by the fi nding that neuronal and astrocytic cell cultures are able to release Guo and Ado under both basal and ischemic conditions .
Multiple Sclerosis
Multiple sclerosis is characterized by multiple symptoms of brain and spinal cord dysfunction that re fl ect degeneration of particular areas of the nervous system that are involved. The affected regions vary between patients and are not speci fi c to the disease. The pathological hallmark is in fl ammatory demyelination and axonal lesions. In fl ammation is primarily driven by autoreactive lymphocytes, which recruit immune cells, such as macrophages, causing tissue damage (Hauser and Oksenberg 2006 ) .
A synthetic nucleoside, cladribine, was shown to be effective in the treatment of multiple sclerosis (Table 29. 2 ). The biologic activity of cladribine is dependent on the preferential accumulation of cladribine phosphates in cells with a high intracellular ratio of deoxycytidine kinase to 5 ¢ NT. Cladribine-phosphates incorporate into DNA, interfering with DNA synthesis and repair and inhibiting enzymes involved in DNA metabolism, such as DNA polymerase and ribonucleotide reductase. This, in turn, leads to DNA strand breaks and, ultimately, cell death (Leist and Weissert 2011 ) . Because activated macrophages, but not neuronal and glial cells, have a high deoxycytidine kinase to 5 ¢ NT ratio (Ceruti et al. 2000 ; Nagata et al. 1984 ) , cladribine can selectively inhibit the damaging in fl ammatory process that occurs in multiple sclerosis.
Inosine may also have bene fi cial effects in the treatment of multiple sclerosis (Markowitz et al. 2009 ) . These data suggest that regional differences in nucleoside system may in fl uence the pathological processes of multiple sclerosis, but further studies are needed to con fi rm this hypothesis.
In conclusion, the current data suggest that nucleoside system offers promising drug targets for the treatment of a variety of brain disorders, including Alzheimer's, Huntington's and Parkinson's diseases, epilepsy, and schizophrenia. Unfortunately, although the nucleoside system has been implicated in the development and treatment of a number of brain disorders, a systematic investigation of the nucleoside system in most brain areas has not yet been performed. These data are needed to elucidate therapeutic strategies driven by the anatomical distribution of nucleoside system. In addition, attention must be given to the effects of gender and age in future studies. These data are eagerly awaited and will help form the foundation for studies of the physiological and pathophysiological functions of nucleosides and for the development of effective treatments for several CNS diseases.
